Victoza
FDA approves Novo Nordisk’s Victoza for children with type 2 diabetes
June 18, 2019Manufacturing and Production GLP-1, Novo Nordisk, Victoza, diabetes, liraglutide
The FDA has approved Novo Nordisk’s Victoza (liraglutide) for paediatric patients aged 10 years and older with type 2 diabetes. …
Novo’s oral semaglutide beats Victoza and Januvia in diabetes
June 21, 2018Research and Development Januvia, MSD, Novo Nordisk, Victoza, pharma, semaglutide
Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue …
Novo Nordisk settles lawsuit over illegal marketing practices for $58.7 million
September 6, 2017Research and Development, Sales and Marketing FDA, Novo Nordisk, US, US Justice Department, Victoza, diabetes, pharma, pharmaceutical
Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities …
Novo Nordisk’s diabetes drug recommended for expanded indication in Europe
June 27, 2017Research and Development, Sales and Marketing CHMP, EMA, EU, Novo Nordisk, Victoza
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to expand the indication of Novo …
FDA backs Novo’s diabetes drug for cardiovascular efficacy
June 21, 2017Research and Development Novo Nordisk, Victoza
Good news for Novo Nordisk as the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommends that data …
Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk
August 5, 2016Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure
Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …
Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients
June 14, 2016Manufacturing and Production, Research and Development Novo Nordisk, Victoza, drug trial, type 2 diabetes
Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of …
FDA committee unanimously recommends Novo Nordisk diabetes combo, IDegLira
May 25, 2016Research and Development, Sales and Marketing FDA, Novo Nordisk, Panel, Tresiba, Victoza, committee, ideglira, recommendation, staff
Novo Nordisk has announced that a US Food and Drug Administration (FDA) advisory committee has unanimously recommended IDegLira, a type-2 …
Novo says Victoza bests MSD’s Januvia at lowering blood sugar
April 4, 2016Research and Development Novo Nordisk, Victoza
Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – …
Novo Nordisk reports five-year Victoza cardiovascular safety data
March 7, 2016Research and Development, Sales and Marketing Novo Nordisk, Victoza
Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …
Novo Nordisk buys Xoma diabetes program and scores trial successes
December 2, 2015Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, SGLT2 inhibitors, Victoza, Xoma, diabetes
Novo Nordisk has announced its purchase of a type 2 diabetes diabetes program in a deal with biotech firm Xoma …
Novo Nordisk looks to HEOR data to back Victoza
November 11, 2015Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness
A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
Novo Nordisk abandons Victoza submission after mixed T1D results
August 26, 2015Research and Development Novo Nordisk, Victoza, diabetes, insulin
Novo Nordisk has been forced to scrap plans to expand its licence for Victoza to include adults with type 1 …
Novo Nordisk obesity drug gets EU approval
March 24, 2015Sales and Marketing EMA, EU, FDA, Victoza, liraglutide, obesity, saxenda
Novo Nordisk’s obesity drug Saxenda has been approved by the European Commission for use across the EU. This approval follows …
